What is IFRX's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.21B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for IFRX?

P/E (TTM) is n/a and 52-week range is €0.80 to €2.95 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s IFRX figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for IFRX?

The company profile lists revenue (TTM) near $29K, net income (TTM) near -$1.24B, EPS (TTM) near -€0.35 when available from the market-data feed. Figures are informational and may lag live markets.

Where is InflaRx NV based, and what identifiers does Chartloom list?

The company context section lists headquarters in Jena, Thueringen, DE, 147.3M shares outstanding, ISIN NL0012661870 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

InflaRx NV

$IFRX

Health Care · Biotechnology

IR Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

InflaRx NV is a clinical-stage biopharmaceutical company, which engages in the discovery and development of inhibitors of the complement activation factor known as C5a and its receptor C5aR. The company is headquartered in Jena, Thueringen and currently employs 65 full-time employees. The company went IPO on 2017-11-08. The firm's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The firm's product pipeline also includes IFX-2, which is in preclinical development.

Employees

Website

www.inflarx.de/

IPO

2017-11-08

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)